PHARMACOLOGY MEGA
PRACTICE EXAM 2026||Questions
And Answers With Rationales/Graded
A+/2026 Update/100% Correct
/Instant Download
Latest Topic Test
For Student School Testing
Total Questions: 285
Format: Multiple Choice | Highlighted Answers | Clinical Rationales
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Q1–35)
1. A drug administered intravenously reaches peak concentration fastest
because:
• A) It undergoes first-pass metabolism
• B) It bypasses absorption barriers
• C) It requires active transport
• D) It binds to plasma proteins
Rationale: IV administration delivers drug directly into systemic circulation,
avoiding absorption phases (GI tract, skin, etc.).
2. Which phase of pharmacokinetics involves conversion of a drug to a more
water-soluble compound?
• A) Absorption
• B) Distribution
• C) Metabolism
• D) Excretion
,Rationale: Metabolism (biotransformation), primarily hepatic, increases polarity
for renal excretion.
3. A drug with a half-life of 4 hours is administered every 4 hours.
Approximately when will steady state be reached?
• A) 8 hours
• B) 12 hours
• C) 20 hours
• D) 40 hours
Rationale: Steady state occurs after 4–5 half-lives (4 × 5 = 20 hours).
4. The therapeutic index (TI) of a drug is calculated as:
• A) ED50/TD50
• B) TD50/ED50
• C) LD50/ED50
• D) ED50/LD50
Rationale: TI = toxic dose for 50% / effective dose for 50%. Lower TI = narrower
safety margin.
5. A weak acid drug (pKa 4.4) is placed in gastric fluid (pH 1.4). It will be
mostly:
• A) Non-ionized, lipid-soluble
• B) Ionized, water-soluble
• C) Ionized, lipid-soluble
• D) Non-ionized, water-insoluble
Rationale: Weak acids are non-ionized in acidic pH (Henderson-Hasselbalch),
favoring absorption.
6. First-pass effect reduces bioavailability of drugs given:
• A) Intravenously
• B) Sublingually
, • C) Orally
• D) Topically
Rationale: Oral drugs pass through liver via portal circulation; hepatic metabolism
may inactivate part of dose.
7. Volume of distribution (Vd) of a drug is 500 L. This suggests:
• A) Drug is confined to plasma
• B) Extensive tissue binding
• C) Drug is highly protein-bound
• D) Impaired renal excretion
Rationale: High Vd (>42 L total body water) indicates sequestration in tissues.
8. Zero-order kinetics is characterized by:
• A) Constant half-life
• B) Saturated elimination pathways
• C) First-order metabolism at low doses
• D) Linear elimination graph
Rationale: Zero-order (e.g., phenytoin, alcohol) → constant amount eliminated per
time, not proportional to concentration.
9. CYP450 enzyme induction leads to:
• A) Decreased drug effect
• B) Increased drug effect
• C) Prolonged half-life
• D) Increased toxicity
Rationale: Induction increases metabolism → lower plasma concentration →
reduced therapeutic effect.
10. Bioavailability of an oral drug is 0.8. If IV dose is 100 mg, oral dose needed
for same effect is:
PRACTICE EXAM 2026||Questions
And Answers With Rationales/Graded
A+/2026 Update/100% Correct
/Instant Download
Latest Topic Test
For Student School Testing
Total Questions: 285
Format: Multiple Choice | Highlighted Answers | Clinical Rationales
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Q1–35)
1. A drug administered intravenously reaches peak concentration fastest
because:
• A) It undergoes first-pass metabolism
• B) It bypasses absorption barriers
• C) It requires active transport
• D) It binds to plasma proteins
Rationale: IV administration delivers drug directly into systemic circulation,
avoiding absorption phases (GI tract, skin, etc.).
2. Which phase of pharmacokinetics involves conversion of a drug to a more
water-soluble compound?
• A) Absorption
• B) Distribution
• C) Metabolism
• D) Excretion
,Rationale: Metabolism (biotransformation), primarily hepatic, increases polarity
for renal excretion.
3. A drug with a half-life of 4 hours is administered every 4 hours.
Approximately when will steady state be reached?
• A) 8 hours
• B) 12 hours
• C) 20 hours
• D) 40 hours
Rationale: Steady state occurs after 4–5 half-lives (4 × 5 = 20 hours).
4. The therapeutic index (TI) of a drug is calculated as:
• A) ED50/TD50
• B) TD50/ED50
• C) LD50/ED50
• D) ED50/LD50
Rationale: TI = toxic dose for 50% / effective dose for 50%. Lower TI = narrower
safety margin.
5. A weak acid drug (pKa 4.4) is placed in gastric fluid (pH 1.4). It will be
mostly:
• A) Non-ionized, lipid-soluble
• B) Ionized, water-soluble
• C) Ionized, lipid-soluble
• D) Non-ionized, water-insoluble
Rationale: Weak acids are non-ionized in acidic pH (Henderson-Hasselbalch),
favoring absorption.
6. First-pass effect reduces bioavailability of drugs given:
• A) Intravenously
• B) Sublingually
, • C) Orally
• D) Topically
Rationale: Oral drugs pass through liver via portal circulation; hepatic metabolism
may inactivate part of dose.
7. Volume of distribution (Vd) of a drug is 500 L. This suggests:
• A) Drug is confined to plasma
• B) Extensive tissue binding
• C) Drug is highly protein-bound
• D) Impaired renal excretion
Rationale: High Vd (>42 L total body water) indicates sequestration in tissues.
8. Zero-order kinetics is characterized by:
• A) Constant half-life
• B) Saturated elimination pathways
• C) First-order metabolism at low doses
• D) Linear elimination graph
Rationale: Zero-order (e.g., phenytoin, alcohol) → constant amount eliminated per
time, not proportional to concentration.
9. CYP450 enzyme induction leads to:
• A) Decreased drug effect
• B) Increased drug effect
• C) Prolonged half-life
• D) Increased toxicity
Rationale: Induction increases metabolism → lower plasma concentration →
reduced therapeutic effect.
10. Bioavailability of an oral drug is 0.8. If IV dose is 100 mg, oral dose needed
for same effect is:
